Estimating the cost to cure licensing gaps is the step that turns a diligence finding into a number the deal team can use. A gap on its own is a statement of risk. The cost to cure is what it actually takes to close that gap, expressed in money and time. When a buyer asks for estimating the cost to cure licensing gaps, they want three figures: what it costs to fix quietly now, what a negotiated settlement would likely cost, and what the worst case looks like if a publisher presses at list price. Without those figures, a licensing gap is just an anxiety, not a deal input.
This guide explains how to build that estimate so it survives scrutiny, as part of the wider software due diligence method and the discipline of quantifying software audit exposure before you sign. The output feeds the deal model and, after close, the license reconciliation plan.
What estimating the cost to cure licensing gaps actually means
The cost to cure is not a single price tag. It is a structured estimate built from the shortfall, the remediation path, and the leverage each side holds. A gap can be cured by buying the missing entitlement, by re architecting the deployment so fewer licenses are needed, by removing the offending usage, or by negotiating a settlement after an audit notice. Each path has a different cost, and the cheapest path before close is rarely the cheapest path after a publisher has issued an audit letter. The estimate has to make those differences explicit.
Build the estimate from shortfall, remediation, and leverage
Start with the measured shortfall from the effective license position: how many cores, users, or subscriptions sit outside entitlement, per publisher. Then cost the remediation path at the rate the buyer could realistically achieve, not the list rate, because a well advised buyer rarely pays list. Then adjust for leverage: a publisher with a strong contractual position and a history of aggressive enforcement commands a higher settlement than one without. The estimate is the product of these three inputs, not a lookup against a price list.
Express the cure as a low, expected, and high range
A single number invites a single objection and gives the committee false precision. A range invites a discussion about reserves, which is the discussion you want. The low case is quiet pre close remediation at negotiated rates. The expected case is a settlement at typical discount after the position is tested. The high case is list price plus back maintenance and any contractual penalty. Showing all three lets the deal team decide how much to price, how much to escrow, and how much to push back to the seller.
Key takeaways
- The cost to cure is three numbers, not one: quiet remediation now, a likely settlement, and a worst case at list plus back maintenance.
- The same gap costs far more to cure after an audit notice than before, so timing is part of the estimate.
- Build the estimate from measured shortfall, achievable remediation rates, and publisher leverage, not a list price lookup.
- A defensible range lets the deal team price, escrow, or push the exposure back to the seller with confidence.
Why timing changes the number
The single biggest variable in the cost to cure is when the cure happens. Before close, a buyer can remediate quietly, buy the shortfall at a negotiated rate, or re architect to avoid it entirely. After a publisher issues an audit notice, the leverage shifts: back maintenance, penalties, and list pricing come into play, and the buyer negotiates from a weaker position. This is why estimating the cost to cure early, while the deal is still being shaped, is worth far more than the same estimate produced after close. The same exposure that could be a price chip becomes a settlement the buyer simply absorbs.
Connect the cure estimate to deal structure
Deal structure changes both the size and the ownership of the cure. In a stock purchase the buyer inherits the gap and the cheapest cure is usually quiet remediation. In an asset purchase or carve out, anti assignment and change of control terms may force fresh licensing at current pricing, which raises the cure cost but may also create a clean break the buyer can use. The estimate should state, per publisher, how the chosen structure moves the number, so the deal team can weigh structure against exposure rather than treating them separately.
Turn the estimate into a deal lever
A cost to cure estimate earns its keep when it changes a deal term. The levers are familiar: a price adjustment that moves the cure into the purchase price, a specific indemnity that hands a defined gap back to the seller, an escrow that reserves cash against a probable cure, or a closing condition that forces remediation before money moves. Match the lever to the exposure profile and present it the way the diligence report frames a recommendation: specific enough to act on.
Recommendations for buyers
- Always present the cure as a low, expected, and high range tied to the measured shortfall, not a single point estimate.
- Estimate the cure early, while the deal is still being shaped, because timing is the biggest driver of the number.
- State per publisher how deal structure moves the cure cost, so structure and exposure are weighed together.
- Match a concrete lever to each exposure and carry the agreed remediation into the post close reconciliation plan.
Separate the one off cure from the ongoing cost
A complete cure estimate has two parts that buyers often blur together: the one off cost to close the existing gap, and the ongoing cost of staying compliant afterwards. Buying the shortfall fixes today. But if the deployment keeps growing, or if the cure involves moving to a subscription that recurs every year, the buyer has also signed up to a forward cost that belongs in the run rate, not just the deal price. A cure that looks cheap as a one off can be expensive as an annuity. The estimate should state both numbers, so the deal team prices the one off as an exposure and carries the ongoing cost into the forward model. Treating the two separately stops a buyer from celebrating a low settlement that quietly raises the cost of running the business for years.
Model the cure under each realistic deal structure
Because deal structure moves the cure cost, the estimate is most useful when it shows the number under each structure still on the table. A stock purchase usually keeps the existing agreements and lets the buyer remediate quietly at negotiated rates. An asset purchase or carve out may break the agreements and force a fresh license at current pricing, which can raise the cure cost but sometimes delivers a cleaner position the buyer would prefer. Presenting the cure as a small matrix, structure against cost, lets the deal team see the licensing consequence of a structuring decision they may be making for tax or liability reasons. A structure chosen without that view can add an avoidable seven figure cure to the deal.
Why an independent estimate carries weight
A cost to cure estimate produced by a party that also sells the cure is conflicted, because the estimator profits from a higher number. An independent, buyer side advisor builds the estimate from the buyer interest alone, benchmarks the achievable rate honestly, and presents a range the committee can trust. That independence is what lets the deal team underwrite the cure as a real number rather than a vendor quote.